Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231178886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Christina H Sherrill und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Certain glucagon-like peptide-1 receptor (GLP-1) agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2-inhibitors) can reduce cardiovascular risk in individuals with type 2 diabetes and cardiovascular disease (CVD). However, these medications can be expensive, potentially limiting their use.
Objectives
The primary objective was to characterize the use of cardioprotective GLP-1 agonists and SGLT2-inhibitors among adults with diabetes with and without CVD. The secondary objective was to investigate the association of socioeconomic factors and health care utilization with the use of these medications.
Methods
Adults aged ≥20 years old with self-reported diabetes, A1c ≥6.5%, or fasting glucose ≥126 mg/dL were identified using the 2015 to March 2020 National Health and Nutrition Examination Survey. The primary outcome was the use of cardioprotective GLP-1 agonists or SGLT2-inhibitors compared in individuals with and without CVD. Secondary analyses included identification of socioeconomic factors and health care utilization associated with the use of cardioprotective antidiabetic medications, stratified by CVD status. Weighted analyses were conducted to account for the complex survey design.
Results
Use of cardioprotective antidiabetic medications was higher in adults with CVD compared to those without CVD (7.8% vs. 4.6%, P = 0.02), which was driven by the use of cardioprotective SGLT2-inhibitors (4.6% versus 1.9%, P = 0.002). Lower income level and less frequent health care visits within the past year were associated with lower likelihood of using these medications. Conclusion and Relevance: Despite preferential use in individuals with diabetes and CVD, the prevalence of cardioprotective antidiabetic medication use remains relatively low. Disparities in use appear to exist based on income level and health care utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA.
- Department of Pharmacy Practice, School of Pharmacy, MCPHS University, Boston, MA, USA.
ORCID-Profile: Christina H Sherrill, Andrew Y Hwang
Zitieren
APA
Sherrill, C. H., & Hwang, A. Y. (2024). Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231178886
Vancouver
Sherrill CH, Hwang AY. Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231178886
BibTeX
@article{Sherrill2024,
author = {Sherrill, Christina H and Hwang, Andrew Y},
title = {Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231178886}
}
EUVIMED